November 1, 2014     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
Takara Bio and Tianjin Medical University in Gene Therapy Project
 

Tokyo, Aug 3, 2011 (JCN) - Takara Bio and Tianjin Medical University, Cancer Institute and Hospital (TMUCIH) have agreed to a collaboration, working together in clinical research of TCR gene therapy against refractory cancer. Both parties wish to start clinical research within two years.

The lymphocytes from patients will be transduced in vitro with the retrovirus vector having the TCR gene, which specifically recognizes the tumor cells. The gene modified lymphocytes will be grown in vitro culture, and then they will be re-infused into patients. These lymphocytes are expected to specifically recognize and attack tumors in the patients.

Although Takara is now doing several clinical development projects concerning cancer and AIDS in Japan as well as in the U.S., this is the first gene therapy project in China. Takara is starting up this TCR gene therapy project, and it plans to further expand its business in the field of the cell and gene therapy.

Takara and Mie University, School of Medicine are now jointly conducting clinical research on TCR gene therapy against refractory esophageal cancer. Takara plans to start the clinical trial in Japan with regard to TCR gene therapy in the fiscal year of 2013. Dr. Steven A. Rosenberg and his colleagues in the U.S. NCI published the results of their clinical trial of TCR gene therapy for melanoma patients in the journal Science in 2006, which reported promising results for this therapy. They employ RetroNectin in the clinical trial, which was developed by Takara. Since that time, several groups including Dr. Rosenberg's group have performed clinical trials showing the efficacy of TCR gene therapy for several kinds of cancers in addition to melanoma.

By Chris Lui Staff Writer

Copyright © 2014 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Takara Bio  News  
  Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy  (May 12, 2014)
  Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy  (Apr 10, 2014)
  Takara Bio to Distribute ZENOAQ's Cell Cryopreservation Medium in Japan, Europe, and North America  (July 26, 2013)
  Takara Bio launches Nippi's iMatrix-511 Worldwide  (July 12, 2013)
  Takara Bio Grants Cellular Dynamics a Commercial License to Use RetroNectin for iPSC Production  (June 24, 2013)
  Takara Bio Licenses Mushroom Production Technology to Sun Toward Tech  (June 13, 2013)
  Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial  (Jan 7, 2013)
  Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA  (Mar 23, 2012)
  Takara Bio and Tianjin Medical University in Gene Therapy Project  (Aug 3, 2011)
  Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma  (Dec 18, 2008)



 Recent  Biotech News   
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)
Nitto Denko Anti-fibrosis Drug with Molecular Targeting DDS Completes Phase-1a Dose Escalation (Apr 24, 2014)
Kaneka, RIKEN Synthesize Bioplastic from Non-food Plant Resources
 (Apr 14, 2014)
Takara Bio Completes Enrollment for Phase I Clinical Trial in the US for HF10 Anti-Cancer Therapy (Apr 10, 2014)
Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S. (Oct 10, 2013)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)